

Sun Pharma Advanced Research Company Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

SPARC receives US FDA response on Venlafaxine NDA

Mumbai, December 17, 2013: Sun Pharma Advanced Research Company Ltd. (SPARC) announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for Venlafaxine Extended-release Tablets, 300mg, an anti-depressant product. A Complete Response Letter is a communication from the FDA to companies that an NDA cannot be approved in its present form.

In the Complete Response Letter, the FDA has requested for some additional studies related to efficacy and safety. Based on the FDA's feedback, SPARC is evaluating the commercial viability of this product.

About SPARC

Sun Pharma Advanced Research Company Ltd is an international pharmaceutical company engaged in research and development of drugs and delivery systems. More information about the company can be found at www.sunpharma.in.

Contact

Nimish Desai
Tel +91 22 6645 5645, Ext 5717
Tel Direct +91 22 66455717
Mobile +91 98203 30182
E mail nimish.desai@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Ext 5606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail miradesai@sunpharma.com